Assenagon Asset Management S.A. Has $1.16 Million Stock Holdings in Henry Schein, Inc. (NASDAQ:HSIC)

Assenagon Asset Management S.A. decreased its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 92.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,977 shares of the company’s stock after selling 214,706 shares during the period. Assenagon Asset Management S.A.’s holdings in Henry Schein were worth $1,163,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Invesco Ltd. lifted its position in shares of Henry Schein by 0.4% during the 4th quarter. Invesco Ltd. now owns 4,963,409 shares of the company’s stock worth $343,468,000 after buying an additional 17,552 shares during the period. FMR LLC raised its stake in Henry Schein by 6.6% during the fourth quarter. FMR LLC now owns 3,498,033 shares of the company’s stock worth $242,064,000 after acquiring an additional 217,143 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Henry Schein by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 3,169,033 shares of the company’s stock valued at $218,762,000 after acquiring an additional 14,876 shares during the period. Palestra Capital Management LLC acquired a new stake in shares of Henry Schein in the 4th quarter valued at $182,988,000. Finally, Fiduciary Management Inc. WI boosted its stake in shares of Henry Schein by 7.2% in the 4th quarter. Fiduciary Management Inc. WI now owns 2,488,335 shares of the company’s stock valued at $172,193,000 after purchasing an additional 167,990 shares in the last quarter. 96.62% of the stock is owned by institutional investors and hedge funds.

Henry Schein Stock Performance

HSIC stock opened at $70.16 on Wednesday. The company has a 50 day moving average price of $68.54 and a 200 day moving average price of $71.34. Henry Schein, Inc. has a fifty-two week low of $60.56 and a fifty-two week high of $82.49. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.38 and a quick ratio of 0.75. The stock has a market capitalization of $8.54 billion, a PE ratio of 21.93, a price-to-earnings-growth ratio of 2.28 and a beta of 0.86.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Monday, May 5th. The company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.11 by $0.04. Henry Schein had a return on equity of 14.87% and a net margin of 3.21%. The company had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.24 billion. During the same quarter in the previous year, the company posted $1.10 earnings per share. The firm’s quarterly revenue was down .1% on a year-over-year basis. Analysts forecast that Henry Schein, Inc. will post 4.74 EPS for the current year.

Analyst Upgrades and Downgrades

HSIC has been the subject of a number of recent analyst reports. Piper Sandler dropped their target price on shares of Henry Schein from $83.00 to $77.00 and set an “overweight” rating for the company in a research report on Wednesday, April 30th. Wells Fargo & Company dropped their price objective on shares of Henry Schein from $80.00 to $75.00 and set an “equal weight” rating for the company in a report on Tuesday, May 6th. UBS Group reduced their target price on Henry Schein from $83.00 to $80.00 and set a “neutral” rating on the stock in a report on Wednesday, February 26th. Barrington Research decreased their price target on Henry Schein from $90.00 to $86.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 6th. Finally, Wall Street Zen downgraded Henry Schein from a “buy” rating to a “hold” rating in a research report on Thursday, April 17th. Six research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $79.30.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.